Globus Medical (GMED) Price & Analysis
GMED Stock Chart & Stats
- Day’s Range
- MXN 1,413.00 - MXN 1,550.00
- 52-Week Range
- MXN 1,000.67 - MXN 1,916.40
- Previous Close
- MXN 1,550.00
- Volume
- 0
- Average Volume (3M)
- 5
- Market Cap
- MXN 196.86B
- Enterprise Value
- MXN 10.37B
- Total Cash (Recent Filing)
- MXN 595.14M
- Total Debt (Recent Filing)
- MXN 111.19M
- Price to Earnings (P/E)
- 19.7
- Beta
- 0.20
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 22.49
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Spine Growth
Broad growth across U.S. and international spine markets indicates durable procedural demand and continued commercial traction. Expansion across multiple geographies can strengthen market position and provide a foundation for sustained revenue growth over the next several quarters.
Cash Generation And Balance Sheet
Very low leverage and strong operating cash generation provide financial flexibility to fund product development, commercial investment, and integration work internally. This reduces balance-sheet pressure while supporting continued investment in the company’s growth opportunities.
Product And Robotic Adoption
Growing utilization of Excelsius technology and higher system deployments support the company’s enabling-technology platform and surgical workflow ecosystem. Increased adoption can create recurring procedure-related demand and reinforce differentiation in spine and adjacent musculoskeletal care.
Bears Say
Enabling Technology Revenue Pressure
The shift toward flexible capital models is reducing near-term cash sales and reported enabling-technology revenue even as deployments grow. This transition can delay revenue recognition, complicate forecasting, and pressure near-term growth until related implant pull-through develops.
Nevro Integration Drag
Nevro’s declining sales and ongoing integration changes are creating a meaningful drag on consolidated growth. Until product development, sales execution, and trial volumes stabilize, the acquisition may require management attention and weigh on revenue progression and operating consistency.
Margin Volatility
Although current profitability is healthy, the decline in gross margin versus 2025 and inconsistent historical results indicate that earnings power remains sensitive to mix, pricing, or cost pressures. Persistent volatility could limit the durability of margin expansion and earnings growth.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
What is Globus Medical’s market cap?
When is Globus Medical’s upcoming earnings report date?
How were Globus Medical’s earnings last quarter?
Is Globus Medical overvalued?
Does Globus Medical pay dividends?
What is Globus Medical’s EPS estimate?
How many shares outstanding does Globus Medical have?
What happened to Globus Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Globus Medical?
What is the TipRanks Smart Score and how is it calculated?
Globus Medical Stock Smart Score
Company Description
Globus Medical
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Keith W. Pfeil
- Employees
- 6,000
- Website
- www.globusmedical.com
- Address
- 2560 General Armistead Avenue, Audubon, PA, 19403-5214, US
Globus Medical (GMED) Earnings & Revenues
GMED Earnings Call
Earnings Call SentimentPositive
Overall the call was constructive: the company reported broad-based revenue growth (including strong U.S. and International Spine), meaningful margin expansion, record non-GAAP EPS, strong cash generation and continued product and commercial momentum. The main near-term headwinds are Enabling Technologies revenue compression due to a strategic shift to flexible capital models and a temporary top-line drag from the Nevro integration and trial cadence. Management provided reaffirmed revenue guidance and raised EPS guidance, signaling confidence in margin leverage and recovery of transitional businesses.
View all MX:GMED earnings summariesGMED Net sales Breakdown
- 92.34% Musculoskeletal Solutions
- 7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |